Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 12/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.58 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.58 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.58 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485082 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL17670572 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Oxalic Acid SCHEMBL3444375 | 0.94 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Oxalic Acid SCHEMBL17673080 | 0.94 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL10597737 | 0.90 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL2566503 | 0.90 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL7478959 | 0.90 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL7537507 | 0.90 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL2912761 | 0.90 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL18717940 | 0.90 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015150947-A1 | A PROCESS FOR THE PREPARATION OF ISAVUCONAZOLE AND ITS INTERMEDIATES | WOCKHARDT LIMITED (IN) | 2015-10-08 | — | — | WO | claimed |
| WO-1999045008-A1 | 3-[4-(4-CYANOPHENYL)THIAZOL-2-Y)]-1-(1H-1,2,4-TRIAZOL-1-YL)-BUTAN-2-OL DERIVATIVES HAVING ANTIFUNGAL ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-10 | — | — | WO | claimed |
| EP-3666762-B1 | METHOD FOR PRODUCING EPOXY ALCOHOL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2022-04-06 | — | — | EP | disclosed |
| EP-3564207-B1 | METHOD FOR PRODUCING ALCOHOL COMPOUND | KANEKA CORP (JP) | 2021-09-15 | — | — | EP | disclosed |
| US-10919829-B2 | Method for producing alcohol compound | KANEKA CORPORATION (JP) | 2021-02-16 | — | — | US | disclosed |
| US-10730861-B2 | Process for producing epoxy alcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-3666762-A1 | METHOD FOR PRODUCING EPOXY ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-20200172520-A1 | PROCESS FOR PRODUCING EPOXY ALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3564207-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND | Kaneka Corporation (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-20190300465-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND | KANEKA CORPORATION (JP) | 2019-10-03 | — | — | US | disclosed |
| WO-2016055918-A1 | NOVEL STABLE POLYMORPHS OF ISAVUCONAZOLE OR ITS SALT THEREOF | WOCKHARDT LIMITED (IN) | 2016-04-14 | — | — | WO | disclosed |
| US-20110087030-A1 | Process for the manufacture of enantiomerically pure antifungal azoles as ravuconazole and isavuconazole | Carbo-Design LLC | 2011-04-14 | — | — | US | disclosed |
| US-20110087030-A1 | Process for the manufacture of enantiomerically pure antifungal azoles as ravuconazole and isavuconazole | Carbo-Design LLC | 2011-04-14 | — | — | US | disclosed |
| WO-2011042827-A1 | PROCESS FOR THE MANUFACTURE OF ENANTIOMERICALLY PURE ANTIFUNGAL AZOLES AS RAVUCONAZOLE AND ISAVUCONAZOLE | CarboDesign LLC (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110021794-A1 | Process for the manufacture of epoxy triazole derivatives | MULLER MARC | 2011-01-27 | — | — | US | disclosed |
| US-7816537-B2 | Process for the manufacture of epoxybutanol intermediates | BASILEA PHARMACEUTICA AG (CH) | 2010-10-19 | — | — | US | disclosed |
| US-20090299073-A1 | Process for the Manufacture of Epoxybutanol Intermediates | MULLER MARC | 2009-12-03 | — | — | US | disclosed |
| EP-1954264-B1 | PROCESS FOR THE MANUFACTURE OF EPOXYBUTANOL INTERMEDIATES | BASILEA PHARMACEUTICA AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-6300353-B1 | FOR THERAPY OF FUNGAL INFECTIONS | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2001-10-09 | — | — | US | disclosed |
| WO-1999045008-A1 | 3-[4-(4-CYANOPHENYL)THIAZOL-2-Y)]-1-(1H-1,2,4-TRIAZOL-1-YL)-BUTAN-2-OL DERIVATIVES HAVING ANTIFUNGAL ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087030-A1 | Process for the manufacture of enantiomerically pure antifungal azoles as ravuconazole and isavuconazole | CYP51A1, ERG28, CYP3A4 | CYP3A4 3/4885CYP2C9 18/4885CYP2C19 13/4885 |
| US-20110021794-A1 | Process for the manufacture of epoxy triazole derivatives | POR, CYP2E1, CYP1A1 | CYP3A4 7/4885CYP2C9 16/4885CYP2C19 20/4885 |
| US-10919829-B2 | Method for producing alcohol compound | ADH1A, ADH1C, MEP1B | CYP3A4 758/4885CYP2C9 1512/4885CYP2C19 1658/4885 |
| US-20090299073-A1 | Process for the Manufacture of Epoxybutanol Intermediates | POR, CYP4A11, CYP1A1 | CYP3A4 15/4885CYP2C9 38/4885CYP2C19 42/4885 |
| US-20200172520-A1 | PROCESS FOR PRODUCING EPOXY ALCOHOL COMPOUND | ERG28, CYP2E1, ADH5 | CYP3A4 32/4885CYP2C9 108/4885CYP2C19 282/4885 |
| US-10730861-B2 | Process for producing epoxy alcohol compound | ERG28, CYP2E1, ADH5 | CYP3A4 32/4885CYP2C9 108/4885CYP2C19 282/4885 |
| US-20190300465-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND | ADH1A, ADH1C, MEP1B | CYP3A4 758/4885CYP2C9 1512/4885CYP2C19 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.